BCRX | Ticker Profile - Titan Protect

BCRX

BioCryst Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · NMS

$8.41

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

13.41

Based on estimated future earnings — lower means cheaper

Rev Growth

+7.5%

Year-over-year revenue change

Profit Margin

-51.7%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$19.00

+126% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 10 analysts covering this stock

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

https://www.biocryst.com

Country: United States Employees: 435 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.640

Good returns relative to risk taken

Kelly Fraction

0.0361

Modest edge detected — smaller position warranted

Calmar Ratio

0.493

Drawdown risk outweighs the returns — higher risk profile

Annual Return

21.8%

Historical annualised return based on price data

Max Drawdown

-44.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.57

Less volatile than the market — more defensive

52W High

$11.31

26% below the year high

52W Low

$6.00

40% above the year low

Avg Volume

5,429,988

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.3%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.77

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

1.91

Healthy liquidity position

Quick Ratio

1.78

Like current ratio but excludes inventory — stricter test

Gross Margin

76.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-2.5%

Profit from core operations before interest and tax

Free Cash Flow

$264M

Positive — the business generates more cash than it spends

Revenue (TTM)

$886M

Total revenue over the last 12 months

Net Income

$-457,983,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$32.00

Target Median

$19.00

Target Low

$13.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go